| Private Placement / Financing Transactions
Odyssey Therapeutics: The company raised $213 million of Series D venture funding from Jeito and TPG on September 10, 2025. Lightspeed Ventures, Dimension, Wedbush Healthcare Partners, Affinity Asset Advisors and other undisclosed investors also participated in the round. The company is an operator of a biotechnology business intended to develop immunomodulators and oncology drugs.
Alchemab Therapeutics: The company raised $114 million of Series A venture funding in a deal led by SV Health Investors, RA Capital Management and Lightstone Ventures on September 9, 2025. Ono Venture Investment, Eli Lilly and DHVC also participated in the round. The company is a developer of protective therapeutics for hard-to-treat diseases, with an initial focus on neurodegenerative conditions and oncology.
NRG Therapeutics: The company raised $67 million of Series B venture funding in a deal led by SV Health Investors on September 8, 2025. Novartis Venture Fund, M Ventures, Caixa Capital Risc, Criteria Bio Ventures, Omega Funds, Brandon Capital and British Business Bank also participated in the round. The company is an operator of a drug discovery platform intended to develop therapeutic approaches to restore mitochondrial function.
SafeHeal: The company raised EUR 45 million of Series C venture funding in a deal led by M&L Group, Solar Eclipse and Asabys Partners on September 10, 2025. Sofinnova Partners and Polis also participated in the round. The company is a manufacturer of a flexible bypass sheath intended to improve the postoperative lives of patients being treated for colorectal cancer.
Noxilizer: The company raised $30 million of venture funding in a deal led by NewVale Capital on September 10, 2025. The company is a developer of nitrogen dioxide sterilization technology designed to serve pharmaceutical, biotech, and medical device manufacturers.
Penguin Ai: The company raised $29.7 million of Series A venture funding in a deal led by Greycroft on September 11, 2025. UPMC Enterprises, Snowflake Ventures, WaterShed Growth Ventures, Overwater Ventures, SemperVirens Venture Capital, ManchesterStory, Canvas Prime, Eric Larsen, John Santelli, Matt Kozlov, California Health Care Foundation and Horizon Blue Cross Blue Shield of New Jersey also participated in the round. The company is a developer of an AI-powered healthcare platform designed for clinical decision support.
Ensho Therapeutics: The company raised $22.5 million of venture funding in the form of debt from undisclosed investors on September 12, 2025. The company is an operator of a biopharmaceutical business intended to develop oral therapies for patients with inflammatory diseases.
BePharBel Manufacturing: The company raised EUR 13.4 million of venture funding from undisclosed investors on September 8, 2025, putting the company’s pre-money valuation at EUR 10.3 million. The company provides end-to-end pharmaceutical development and manufacturing services for small molecule drugs, antibiotics, and medical devices.
Enlaza Therapeutics: The company raised $15 million of venture funding from undisclosed investors on September 10, 2025. The company is a developer of covalent protein therapeutics intended to deliver efficacious and safer treatments by forming a permanent bond with their disease-related targets.
Aspect Analytics: The company raised EUR 10 million of Series A venture funding in a deal led by Participatiemaatschappij Vlaanderen on September 9, 2025. HERAN Partners, Capricorn Partners, KU Leuven, and other undisclosed investors also participated in the round. The company is a developer of mass spectrometry imaging software designed to bridge the gap between algorithmic development in bioinformatics research and enterprise-grade software.
Vaxess Technologies: The company raised $7.9 million of venture funding in the form of convertible debt from undisclosed investors on September 8, 2025. The company is a developer of novel therapies designed to help in oncology care and infectious diseases.
Patients Know Best: The company raised GBP 4.5 million of venture funding from DNV, and other undisclosed investors on September 11, 2025, putting the company’s pre-money valuation at GBP 32.2 million. The company is a developer of a software-as-a-service platform designed to store health information in a single place.
Cellvie: The company raised $5 million of venture funding in a deal led by Taiho Ventures on September 9, 2025. Beiersdorf and Kizoo Technology Capital also participated in the round. The company is a developer of mitochondria-based therapeutic technology intended to restore cellular bioenergetics and improve organ function.
Arzeda: The company raised $4.5 million of venture funding from undisclosed investors on September 11, 2025. The company is a developer of a synthetic biology technology designed to create new proteins and enzymes with less risk.
Nacuity Pharmaceuticals: The company raised $4.5 million of venture funding in a deal led by Retinal Degeneration Fund and Foundation Fighting Blindness-National Neurovision Research Institute on September 13, 2025. The company is an operator of a biotechnology business intended to offer treatments for retinitis pigmentosa and other ophthalmological disorders.
BoobyBiome: The company raised GBP 2.5 million of venture funding in a deal led by Empirical Ventures on September 8, 2025. Kayan Ventures, Lavender Ventures, The Helm, XFactor Ventures, Evenlode Foundation and other undisclosed investors also participated in the round. The company is an operator of a microbiome research platform intended to improve infant health.
BranchLab: The company raised an undisclosed amount of venture funding from Next Ventures on September 8, 2025. The company is a developer of an AI-native platform designed to improve how healthcare marketers identify and engage high-value patient audiences.
Dewpoint Therapeutics: The company raised an undisclosed amount of Series D venture funding on September 10, 2025. The company is a developer of an AI-powered healthcare technology platform designed to identify novel drugs across a wide spectrum of diseases.
|
